抗菌和生物相容性气管插管-猫眼课题宝

抗菌和生物相容性气管插管

批准号：

9763984

负责人：

XUEJUN WEN

金额：

$70.89万

依托单位：

WYNNVISION, LLC

依托单位国家：

美国

项目类别：

财政年份：

2018

资助国家：

美国

项目状态：

已结题

起止时间：

2018-08-15 至 2021-04-30

来源：

https://reporter.nih.gov/project-details/9763984

关键词：

Animal Model Antibiotics Cells Centers for Disease Control and Prevention (U.S.)Cessation of life Charge Chemistry Clinical Research Culture Media Dermal Devices Diagnosis Effectiveness Elderly Enterobacteriaceae Escherichia coli Esophagus Evaluation Event Fibroblasts Heavy Metals Hour Human In Vitro Incidence Infection Intratracheal Intubation Intubation Klebsiella pneumonia bacterium Lead Legal patent Mechanical ventilation Modeling Modification Mucous body substance Nosocomial pneumonia Oryctolagus cuniculus Outcome Patients Phase Polyethylene Glycols Process Pseudomonas aeruginosa Reporting Research Silicones Silver Staphylococcus aureus Technology Testing Trachea Trauma Tube United States Ventilator Viscosity Work antimicrobial biomaterial compatibility design endotracheal fighting flasks fungus high risk in vitro testing in vivo in vivo evaluation innovation multidisciplinary nano neonate new technology novel strategies off-patent pathogen patient safety prevent scale up ventilator-associated pneumonia

项目摘要

项目成果

XUEJUN WEN的其他基金

相似基金

相关文献

中文摘要

翻译

呼吸机相关性肺炎（VAP）发生后48-72小时（或更长时间）

英文摘要

Ventilator-associated pneumonia (VAP) occurs 48–72 hours (or more) following endotracheal intubation and accounts for half of all cases of hospital-acquired pneumonia. CDC reports and many clinical studies point to a critical need for preventing ventilator associated infections rather than fighting an often losing battle against acquired infection. Responding to this unmet need, WynnVision LLC, “WV” will leverage strong preliminary results for antimicrobial-but-cytocompatible (ABC) nano- overcoats on as-manufactured intubation products to develop a new technology for eliminating or greatly reducing VAP/VAE. The WV approach, protected by a recent patent application, will involve multidisciplinary activities and third party testing to facilitate approaching FDA for approval.

期刊论文(0)

专著(0)

科研奖励(0)

会议论文